Affimed Announces Leadership Change and Organizational Restructuring
January 08, 2024 08:00 ET
|
Affimed N.V.
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go...
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
January 03, 2024 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
December 11, 2023 06:02 ET
|
Affimed N.V.
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort Responses observed in 4 of...
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
December 11, 2023 06:00 ET
|
Affimed N.V.
In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR) was 97% and the complete response (CR) rate...
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
December 04, 2023 06:30 ET
|
Affimed N.V.
Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203Review clinical data for AFM24 in solid...
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 14, 2023 06:30 ET
|
Affimed N.V.
Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024.Acimtamig: Received fast-track designation...
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
November 09, 2023 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
November 07, 2023 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 03, 2023 12:05 ET
|
Affimed N.V.
Addition of Affimed’s innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells...
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
November 02, 2023 09:05 ET
|
Affimed N.V.
In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a...